Insulin glargine use and cancer risk among patients with type 2 diabetes mellitus: a real-world study in Shanghai, China
ConclusionInsulin glargine is not associated with the risk of overall and site-specific cancers compared to NPH insulin among patients with type 2 diabetes mellitus.
Source: International Journal of Diabetes in Developing Countries - Category: Endocrinology Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Insulin | Lantus | Study